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Abstract: Actin filaments play a critical role in the normal physiology of lenticular and retinal cells
in the eye. Disruption of the actin cytoskeleton has been associated with retinal pathology and lens
cataract formation. Ocular toxicity is an infrequent observation in drug safety studies, yet its impact
to the drug development process is significant. Recognizing compounds through screening with a
potential ocular safety liability is one way to prioritize development candidates while reducing
development attrition. Lens epithelial cells from human, dog, and rat origins and retinal pigmented
epithelium cells from human, monkey, and rat origins were cultured and investigated with
immunocytochemical techniques. Cells were treated using noncytotoxic doses of the compound,
fixed, stained for actin with rhodamine phalloidin, and counterstained for nuclei with TOTO-3,
followed by confocal imaging. Tamoxifen and several experimental compounds known to be in vivo
lens and retinal toxicants caused a reduction in F-actin fluorescence at noncytotoxic concentrations in
all cells tested as observed by confocal microscopy. Developing an assay that predicts ocular toxicity
helps the development process by prioritizing compounds for further investigation. Drug-induced
cytoskeletal alterations may be useful as a potential safety-screening marker of retinal and lens
toxicity. The knowledge of actin molecular biology and the application of other mechanistic screens
to toxicology are discussed. Reducing this work to a high-throughput platform will enable chemists
to select compounds with a reduced risk of ocular toxicity.
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Introduction
ACTIN CYTOSKELETON is essential in maintaining ocu-lar cell symmetry and architecture—ultimately pre-
serving lens transparency and refractive power—as it
plays a key role in the correct physiological function of
the lens and retinal pigmented epithelium. Although re-
cent studies have demonstrated the effects of drug tox-
icity on a group of proteins known to regulate the orga-
nization of the actin cytoskeleton, little is known about
the effects of ophthalmologic-toxic agents on actin it-
self.1–3 Observations drawn from studies in cell biology
as well as those documenting the effects of pharmaco-
logic agents on the eye suggest that changes in the struc-
ture of actin filaments could serve as a potential marker
of drug-induced retinal and lens toxicity.3–10
Both the retinal pigmented epithelium and lens ep-
ithelium carry out several functions that are crucial for
the normal function of the eye. Located between the pho-
toreceptors and the choiroid, retinal pigmented epithelial
cells function mainly to support the overlying photore-
ceptor cells. They carry out this support function by trans-
porting nutrients, storing vitamin A, absorbing stray light
not absorbed by the photoreceptors, and—perhaps most
critically—undertaking the “scavenging” role of phago-
cytosis of the rod outer segments.11–14 Lens epithelial
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cells are located under the anterior lens capsule. They mi-
grate, proliferate, and differentiate into lenticular fiber
cells at the equatorial bow of the lens.4 As these cells be-
come part of the cortex, they elongate and begin losing
organelles such as nuclei and mitochondria. The actin cy-
toskeleton plays several important roles in the function-
ing of the lens and retinal pigmented epithelium. Actin
is associated with adherent junctions between fiber and
epithelial cells, and it contributes to the migration and
elongation of lens cells.4,5 During tension and the pro-
cess of accommodation that occur in the eye, actin fila-
ments form polygonal arrays that stabilize the lens. With
respect to retinal pigmented epithelial cells, actin micro-
filaments are essential for correct internalization and
phagocytosis of outer segments, and the microfilaments
are a key component of microvilli protrusions that sur-
round rod outer segments.15–17
Understanding the biochemical and molecular mecha-
nisms that control the organization of actin is therefore a
major goal of contemporary cell biology, with implica-
tions for health and disease. On a molecular level, actin
is regulated directly via the Rho family of small G pro-
teins, including Rho, Rac, and Cdc42.6,18,19 In addition,
extensive crosstalk takes place between guanosine triphos-
phatases (GTPases) of the Ras and Rho subfamilies: both
Ras and Cdc42 can activate Rac, while Rac in turn can
activate Rho. Cdc42, Rac, and Rho proteins also play a
cooperative role in the protein-induced transformation of
the Ras subfamily.20–22 Based on such observations, re-
searchers such as Hall6 have suggested that Rho GTPases
are key regulatory molecules linking surface receptors to
the organization of the actin cytoskeleton. Consequently,
many factors can affect actin assembly by influencing the
Rho family of proteins.
In recent years, studies have linked Rho-regulated actin
cytoskeleton organization with corneal epithelial migra-
tion, with implications for corneal disease.1,2 It is sug-
gested that cholesterol-lowering drugs such as lovastatin
impair Rho and Rac GTPase function, leading to cy-
toskeletal changes in lens epithelial cells. The implica-
tions for cataract formation are significant. Pretreatment
of lens epithelial cells with such agents as the Rho-
GTPase inhibitor C3-exoenzyme interferes with the abil-
ity of certain growth factors to trigger activation of Rho
and Rac GTPases and, by extension, actin stress fiber and
focal adhesion formation.3
Research has been published in recent years on actin
cytoskeleton from a microbiological perspective.7,23,24
Although enough is known about the effect of certain po-
tent pharmaceutical agents on the eye to raise clinical
concerns, much less is known about the effect of drug
toxicity at the molecular level.25–27 It is thought that
changes in the structure of actin microfilaments poten-
tially may reflect injury to lens and retinal pigmented ep-
ithelial cells consistent with the effects of drug toxicity,
but this has not been widely demonstrated.5,28–30 What
is clear is that toxicity in the eye can be caused by a wide
array of medications, resulting from heterogeneous forms
of pathogenesis and leading to a diverse set of adverse
effects.25 Sometimes the effects are directly related to
drug exposure itself; at other times they can be caused
by secondary effects of the drug (e.g., metabolic prod-
uct/biotransformation to reactive intermediate). Some of
the observed side effects are reversible; others are not.
For example, tamoxifen, an oral anti-estrogen used in the
treatment of breast cancer, has been associated with such
eye problems as cataracts and retinopathy.26,31,32 Fur-
thermore, tamoxifen has been shown to inhibit phagocy-
tosis of rod outer segments,14 an important function of
retinal pigmented epithelial cells and a function for which
action microfilaments are essential. If the cytotoxicity of
a drug such as tamoxifen could be shown to affect the
cytoskeleton early, before cytotoxicity has been known
to occur using such standard assays as the WST-1 dye
test, actin could potentially serve as a marker of drug-in-
duced lens and retinal changes preceding loss of cell vi-
ability.
Early in vivo toxicology assessment of drug develop-
ment candidates traditionally focuses on the “big” organs,
such as the liver, kidneys, heart, brain, lung, and testis,
since these are major causes of toxicity-related develop-
ment attrition. Ocular toxicity, on the other hand, is not
really evaluated until much further in development and,
when identified, can be much more costly to a program,
since this is a significant finding that tends to be a de-
velopment stop. Industrial toxicology over the past
decade has switched from risk identification to risk man-
agement. This is fine for liver toxicity where serum
chemistries can be correlated to potential liver injury. In
cases of ocular toxicity, there are few risk management
tools, and the acceptability of these safety risks is very
low. With this knowledge in mind, efforts to reduce late-
stage attrition by identifying toxicity screening assays
have increased in the area of toxicology. When there are
thousands of drug candidates to evaluate, and it is known
that a certain pharmacology or chemical structure is pre-
disposed to cataract formation, any indication or ability
to prioritize compounds is warranted. In our investiga-
tion into developing a screen for ocular toxicity, we had
the benefit of knowing the in vivo result and are work-
ing to reverse-engineer an in vitro screen that could be a
predictive marker of imminent lens toxicity.
This research effort grew out of a set of cell culture
experiments evaluating different preparation methods for
evaluating the cytoskeleton. In a parallel set of investi-
gations, we were brainstorming opportunities to screen
away from potential ocular toxicity through the develop-
ment of a cell viability assay. Many cell lines were at our
disposal. Why actin and not microtubules became the
eventual focus of the effort centered on an observation
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associated with the cell viability screening, namely,
that with increasing concentration of drugs with known
in vivo cataract liability, a concomitant in vitro cell
death also occurred. And when these cells died, they
lifted from the plate. Since cell adhesion in culture
tends to be mediated by actin, we looked for changes
in actin preceding loss of adhesion as a possible marker
of cellular toxicity. Actin staining was also observed
not to change in culture when using compounds of sim-
ilar pharmacology but without cataracts, hence the pos-
sibility of actin change to screen for cataract potential.
By evaluating the organization of the F-actin cy-
toskeleton using confocal microscopy, quantifying the
fluorescence of F-actin, and assessing cell viability
over the 24-h treatment period, this study sought to in-
vestigate the extent of structural modification in actin
filaments seen in cells exposed to increasing concen-
trations of tamoxifen before evident cytotoxicity was
present. We are continuing to investigate the sensitiv-
ity and specificity of this assay to predict or translate
into a cataract liability. Utilizing this screen, even with-
out this quantitative information, does achieve the goal
of helping prioritize development candidates, as these
potential failures could be tested by collecting the eyes
early than normal in the discovery process.
Materials and Methods
In this study, lens epithelial cells (human and rat) and
retinal pigmented epithelial cells (human, monkey, and
rat) were grown to 80% confluency, treated for 24 h with
increasing concentrations of tamoxifen, and compared to
untreated controls using a variety of measures as ex-
plained in the following sections.
Primary cell culture
Sprague-Dawley rats and primates were obtained
from Charles River (Wilmington, MA); eye collection
was carried out in accordance with guidelines of the
Association for Research in Vision and Ophthalmology
for animal care and use. Following enucleation, mon-
key and rat eyes were opened by an incision at the ora
serrata, followed by a circumferential incision to sep-
arate the posterior segment of the eye from the ante-
rior segment, in order to harvest the retina. For mon-
key retinal pigmented epithelial cell lines, the posterior
segment was placed in an eye holder and washed with
Puck’s saline F solution (containing the following
wt/vol concentrations in water: 0.74% NaCl, 0.018%
Na2HPO4, 0.0083% KH2PO4, 0.03% KCl, 0.12%
NaHCO3, 0.11% glucose, and 0.0034% EDTA) at pH
7.12. The retinal layer was gently removed. Once clean,
this tissue was incubated for 40 min in 0.25% trypsin
at 37°C. Trypsin medium was collected and placed in
a 15-ml Falcon tube together with 10 ml of Dulbecco’s
Modified Eagle’s Medium (DMEM) (GIBCO®, Grand
Island, NY) containing 15% fetal bovine serum (FBS)
(Hyclone, Logan, UT) and spun at 500 rpm for 5 min.
This incubation/collection with trypsin and DMEM
containing 5% FBS was repeated for at least seven
times, removing the supernatant and concentrating the
cells into a soft pellet. The final cell pellet was added
to DMEM containing 15% FBS to a cell culture flask.
Cells were then plated at a density of 4  104 cells/cm2
cells in a T25 flask with DMEM containing 15% FBS,
1% L-glutamine (GIBCO), and 1% penicillin-strepto-
mycin (GIBCO). Cells were maintained for 2 weeks in
95% air and 5% CO2 at 37°C under 100% humidity.
RPE-J is a commercially available retinal pigmented
epithelial cell line derived from primary cultures of
retinal pigmented epithelial cells taken from 7-day-
old Long-Evans rats (http://www.atcc.org/common/
catalog/numSearch/numResults.cfm?atccNumCRL-
2240).
Rat primary lens epithelial cells were isolated by sep-
arating the capsule from the lens nucleus. The lens cap-
sule was added to unsupplemented collagenase medium
(1 mg/ml), incubated at 37°C, and monitored every 3–5
min for dissociation. Cells were then plated on dishes
coated with collagen IV at a density of 1  104 cells/cm2
(Biocoat Cellware, collagen type IV, VWR 62405, Bec-
ton Dickinson, San Jose, CA). Growth medium consist-
ing of DMEM low glucose (GIBCO), 15% FBS, 1% peni-
cillin-streptomycin, 1% L-glutamine, and 25 mM HEPES
was added. Cells were grown to confluence before being
trypsinized and plated for experiments.
Cell line culture
The rat retinal pigmented epitheial cell line RPE-J was
grown in DMEM containing 4% FBS, 0.1 mM nonessen-
tial amino acids, and 4.5 g/L glucose. Cells from a hu-
man RPE cell line (ARPE-19) were treated with
DMEM/F-12 medium (GIBCO) containing 10% FBS and
2 mM L-glutamine and maintained in 95% air and 5%
CO2 at 37°C under 100% humidity. A human lens ep-
ithelial cell line (hLEC SRA 04/01) was established by
transforming primary lens cells with a large T-antigen of
SV40.33 Cells were grown in DMEM containing 15%
FBS in a mixture of 95% air and 5% CO2 at 37°C under
100% humidity.
Cell plating and treatments
For the F-actin assay, all cells were plated in four-
chamber, polystyrene, tissue-culture-treated glass slides
(Falcon BD, San Jose) at a density of 5  104 cells per
chamber. Once the cells reached 80% confluency, they
were treated with increasing concentrations of tamoxifen
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(tamoxifen citrate, Calbiochem, San Diego, CA). Cells
were grown to 80% confluency and treated with in-
creasing concentrations of tamoxifen. With a mixture of
cell lines and primary cell cultures in this investigation
and using cell viability assays as a guide, it should be
noted that each cell line responds differently to tamox-
ifen exposure. Given that some cultures are more robust
or react differently to the stresses of culture in this screen-
ing study, tamoxifen concentrations were optimized per
culture to create exposures of a nontoxic, upper limit of
viability, and cytotoxic levels.
F-actin staining and confocal microscopy
Cultured cells were rinsed twice in phosphate-
buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO),
fixed with 4% paraformaldehyde (Electron Microscopy
Sciences, Hatfield, PA) at room temperature for 30 min,
and rinsed again in PBS. To quench any remaining
paraformaldehyde, cells were incubated for 10 min in
100 mM PBS/glycine (Sigma-Aldrich). Fixed cells
were permeabilized for 20 min at room temperature
with 0.1% Triton X-100 (Sigma-Aldrich) in PBS. Cells
were incubated for 1 h in a solution containing 1%
bovine serum albumin (Roche, Indianapolis, IN), 1
mg/ml RNase A (Sigma-Aldrich), and PBS. Stock of
rhodamine phalloidin (Molecular Probes, Eugene, OR),
which was made by adding 1.5 ml of methanol to 300
U of solid stock, was diluted in blocking buffer by a
ratio of 1:400, resulting in a final concentration of 100
nM. F-actin and nuclei were detected by incubating
cells for 1 h with rhodamine phalloidin and 1 M
TOTO-3 (Molecular Probes) in PBS. Following stain-
ing, cells were washed three times in PBS at room tem-
perature, each time for 5 min. Coverslips (24 ( 50 mm,
VWR, West Chester, PA) were mounted onto a slide
face down, with the use of a mounting anti-fade solu-
tion (Molecular Probes). After 24 h of incubation in the
dark, fingernail polish was used to seal the slide. Con-
focal microscopy was performed with a Leica SP laser-
scanning microscope (Leica, Heidelberg, Germany) us-
ing an objective of 40 (1.25 numerical aperture [NA])
with oil.
Cell viability
Cells were cultured in 96-well plates (Costar, Corning,
NY) at 1  104 cells per well and grown to 80% con-
fluency. After being treated for 24 h with increasing con-
centrations of tamoxifen, cells were washed twice in PBS
using a soaking pipette (VWR, West Chester, PA), and
WST-1 reagent was added to the cells for 3 h at a ratio
of 100 l/ml of cell medium. The wells were analyzed
by an enzyme-linked immunosorbent assay plate reader
(Spectra Max Plus 384, Molecular Devices, Sunnyvale,
CA) at a wavelength of 440 nm.
Results
By treating a series of human and animal lens and reti-
nal cells to increasing concentrations of tamoxifen for 24
h and comparing the outcomes to those in untreated con-
trols, we were able to detect significant structural changes
in (or affecting) the cells’ actin filaments. For each group
of cells, qualitative presentations of actin cytoskeleton
using confocal microscopy demonstrating fluctuation in
F-actin fluorescence and cell viability are provided. With
the rat RPE-J cells, treated with concentrations of ta-
moxifen of 2.5 M, 10 M, and 50 M, there was a de-
tectible reduction in cell viability only at the highest con-
centration, while decreases in F-actin fluorescence were
quantifiable beginning with the lowest concentration
(Fig. 1). At 2.5 M actin concentration was 80% of the
concentration of untreated controls, and at 10 M it was
still more than 50%. However, at 50 M, actin concen-
tration dropped to 40%. The qualitative images derived
from confocal microscopy show that, as the concentra-
tion of tamoxifen increases, an increasing number of actin
fibers are lost, suggesting a concentration-dependent re-
lationship.
We assessed the effect of tamoxifen on human ARPE-
19 cells, treated with concentrations of the drug of 1
M, 12.5 M, and 25 M (Fig. 2). The quantification
of F-actin indicated that there was a loss of fluorescence
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FIG. 1. Rat retinal pigmented epithelial cell line (RPE-3) was
treated for 24 h with increasing concentrations of tamoxifen (A,
0 µM; B, 2.5 M; C, 10 M; and D, 50 M). F-actin cy-
toskeleton was stained with rhodamine phalloidin (red), and nu-
clei were stained with TOTO-3 dye (blue). Qualitative presen-
tation of actin cytoskeleton using confocal microscopy (40
objective, 1.25 NA) shows a concentration-dependent loss of
actin fibers with increasing concentration of tamoxifen.
(to 50% of that of controls) at low concentrations of
tamoxifen (1 M). This loss is also reflected in the qual-
itative presentation, in which can be seen the decrease
in F-actin at the lower concentrations of tamoxifen (1
M and 12.5 M) leading to eventual clumping at the
highest concentration at which the ARPE-19 cells were
tested (25 M). This aggregation of F-actin, along with
the loss of actin stress fibers, may provide the explana-
tion for why a slight increase in fluorescence was seen
at 25 M tamoxifen (where it was 60% of that of con-
trols, more than twice the F-actin concentration at 12.5
M). The third and final sets of retinal cells that we in-
vestigated were monkey primary retinal pigmented ep-
ithelial cells, and these were also treated with concen-
trations of tamoxifen of 1 M, 12.5 M, and 25 M.
Loss of F-actin fluorescence paralleled drops in cell vi-
ability but only at higher concentrations of tamoxifen
(Fig. 3). At the 1 M treatment, the concentration of F-
actin fluorescence actually increased 20% to that seen
in untreated controls, and it was at 100% with 12.5 M
treatment, where cell viability began to drop to just be-
low 80% of controls. The qualitative presentations sug-
gest that the loss of actin fibers began as early as 1 M
treatment, and mirrors the loss in F-actin fluorescence
only at 25 M.
Our assessment of lenticular cells resulted in com-
parable findings overall, but with even more precipi-
tous drops in F-actin fluorescence than we saw with
retinal cells. In rat primary lens epithelial cells treated
with concentrations of tamoxifen of 5 M, 25 M, and
75 M, the amount of F-actin fluorescence fell from
120% of the amount of controls at 5 M to approxi-
mately 1% at 25 M (Fig. 4) using a median measure-
ment of the entire red channel (actin) and count of the
nuclei in the blue channel. It should be noted that this
reduction occurred at concentrations of tamoxifen con-
sidered to be noncytotoxic, and it is mirrored by the
notable loss of actin fibers between 5 M and 25 M
treatment that is apparent in the confocal microscopy
images. We also examined cells from a human lens ep-
ithelial (SRA) cell line treated with concentrations of
tamoxifen of 5 M, 25 M, and 50 M. As we saw
with human retinal pigmented epithelial cells, there was
a reduction in F-actin fluorescence at low, noncytotoxic
concentrations of the drug (Fig. 5). This is shown in
the qualitative presentation to be a rapid drop (to 40%
of the amount of F-actin of untreated controls). At 25
M, F-actin fluorescence increased to 60% of that of
controls. Tamoxifen has started to become cytotoxic,
resulting in the aggregation of actin fibers. Cell via-
bility began to drop rapidly at concentrations 25 M,
suggesting that these levels are progressively cytotoxic.
At 50 M tamoxifen, a total loss of microfilaments is
observed via confocal microscopy.
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FIG. 2. Human retinal pigmented epithelial cell line (ARPE-
19) was treated for 24 h with increasing concentrations of ta-
moxifen (A, 0 M; B, 1 M; C, 12.5 M; and D, 25 M).
Qualitative presentation of actin cytoskeleton using confocal
microscopy (40 objective, 1.25 NA) shows a loss of F-actin
at low noncytotoxic concentrations of tamoxifen (1 M), lead-
ing to eventual clumping at higher concentrations (25 M).
FIG. 3. Monkey primary retinal pigmented epithelial cells
were treated for 24 h with increasing concentrations of tamox-
ifen (A, 0 M; B, 1 M; C, 12.5 M; and D, 25 M). Quali-
tative presentation of actin cytoskeleton using confocal mi-
croscopy (40 objective, 1.25 NA) shows a loss of actin
fluorescence at higher concentrations of tamoxifen.
Discussion
In this study, we demonstrated that tamoxifen, known
to be a lens and retinal toxicant in vivo, caused a reduc-
tion in F-actin fluorescence at noncytotoxic concentra-
tions in all cell types tested. These findings suggest that
drug-induced cytoskeletal alterations may be useful as an
early marker of retinal and lens toxicity. If this new ap-
plication of actin cytoskeleton can be qualified through
the use of other drugs and compounds, it may point the
way toward the development of an assay that could pre-
dict drug toxicity before any ocular damage becomes ir-
reversible.
The rationale for why changes in actin cytoskeleton
could serve as an early marker of toxicity to the eyes is
based on a broad and diverse set of findings derived from
studies in cell biology, ophthalmology, and toxicology.
Furthermore, as much as is known about actin’s direct
role in cell growth, differentiation, morphogenesis, and
motility, recent observations about the association of
actin with other cellular proteins and growth factors have
proven to be a comparably rich source for informing our
working hypothesis about the effects of drug toxicity on
the cytoskeleton.
Within the realm of cell biology, actin has been vividly
described by McGough7 as “the molecular railroad track
for myosin, the internal scaffold for microvilli, the mo-
lecular drill of the acrosomal reaction, and the comet on
which pathogens travel.” Discovered more than 50 years
ago, purified from muscle, the protein is now recognized
as the 42-kDa actin monomer (G-actin), which assembles
itself in vitro as well as in vivo to form long helical fil-
aments known as F-actin. While much of our under-
standing of actin filaments comes from in vitro studies
of the pure form of actin, the assembly and function of
actin in the cell are governed by other proteins that bind
actin. It is the interactions of these proteins34 that result
in what McGough7 described as the “beautiful ballet” un-
derlying cell differentiation and motility. “Disruptions in
these processes,” she wrote, “are the basis of many ge-
netic diseases as well as of both viral and bacterial in-
fectivity.”
What becomes clear from a review of the literature de-
tailing the many associations of actin cytoskeleton is that,
even when it is not the central focus of a particular av-
enue of research, the protein remains at the center of pro-
cesses within and affecting the cell. These associations
include, but are not limited to, those involving micro-
tubule dynamics and tubulin-interacting proteins,35,36
membrane trafficking and organelle transport,37 the
WASP family of proteins and the Arp2/3 complex,38 gel-
solin, villin, tropomodulin, and actin depolymerizing fac-
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FIG. 4. Rat primary lens epithelial cells were treated for 24
h with increasing concentrations of tamoxifen (A, 0 M; B, 5
M; C, 25 M; and D, 75 M). Qualitative presentation of
actin cytoskeleton using confocal microscopy (40 objective,
1.25 NA) shows a loss of actin fluorescence at noncytotoxic
concentrations of tamoxifen (25 M).
FIG. 5. Cells from a human lens epithelial cell line (SRA
04/01) were treated for 24 h with increasing concentrations of
tamoxifen (A, M; B, 5 M; C, 25 M; and D, 50 M). F-
actin cytoskeleton was stained with rhodamine phalloidin (red),
and nuclei were stained with TOTO-3 dye (blue). Qualitative
presentation of actin cytoskeleton using confocal microscopy
(40 objective, 1.25 NA) shows a rapid drop in F-actin fluo-
rescence at concentrations as low as 5 M. At 25 M tamox-
ifen is starting to become cytotoxic, and actin fiber aggregation
is observed. Finally, at 50 M drug there is a total loss of mi-
crofilaments.
tor (ADF)/cofilin,36 intracellular bacterial pathogens such
as Listeria and lamellipodial and filopodial protrusion,24
and proteins that link integrins to the actin cytoskeleton,
including talin, vinculin, -actinin, and filamin.39 Ar-
guably, one of the most important cellular associations
of the actin cytoskeleton involves the Rho family of small
GTPases.6,18,23 Rho GTPases regulate several actin-
based cellular processes, including cell adhesion, cytoki-
nesis, and contraction.19 By inducing coordinated
changes in the organization of the actin cytoskeleton, Rho
GTPases serve as molecular switches, activating biolog-
ical responses ranging from morphogenesis to cell cycle
guidance.6 Rho also plays a role in signaling pathways
leading to the formation of actin stress fibers and focal
adhesions—for example, in fibroblasts stimulated by
lysophosphatidic acid (LPA). In 1997 Amano et al.18
showed that microinjection into serum-starved Swiss 3T3
cells of the catalytic domain (CAT) of Rho-kinase, a tar-
get protein activated by Rho, induced the formation of
actin stress fibers and focal adhesions. Microinjection of
three of the other four domains of Rho-kinase inhibited
the LPA-induced formation of stress fibers and focal ad-
hesions. Because injection of the CAT of Rho-kinase
slightly increased the intensity of phalloidin staining, the
authors conclude that Rho-kinase may marginally induce
actin polymerization. Randomly arranged F-actin was ob-
served in cells stimulated by LPA in the presence of the
protein kinase inhibitor staurosporine, but not in cells in-
jected with CAT in the presence of staurosporine.
Functional aberrations involving regulatory proteins
such as Rho GTPases have been associated with various
pathological conditions, as can be seen in several oph-
thalmologic studies centered on the lens.4 A transparent
organ containing many proteins, the lens is responsible
for focusing light on the retina, a process that requires
the lens to vary its refractive power via accommodation—
i.e., by changing its shape. During growth of the lens,
lens epithelial cells divide, lengthen, and differentiate
into fiber cells. Differentiation remains an ongoing pro-
cess throughout life, characterized by the synthesis and
accumulation of cystallins, soluble proteins found in
abundance in the lens. The accumulation of two crys-
tallins in particular—A- and B-crystallin—has been
associated with several neoplastic and neurological dis-
orders.4 In the lens, both proteins are known to undergo
changes via phosphorylation and bind such cytoskeletal
proteins as actin.
Despite gains made in recent decades in understand-
ing lens biology, much remains unclear about the mo-
lecular processes regulating cytoskeletal organization,
differentiation of fiber cells, and the abundance of crys-
tallins in the lens—particularly as they relate to lens dys-
function and the formation of cataracts. In the early
1990s, analysis of Rho, newly identified as a member of
the Ras superfamily of small GTPases, showed that its
activation led to actin stress fiber formation—introduc-
ing yet another piece of the molecular puzzle.6 In a study
published in 1997 using GTP blot overlay assays, Rao et
al.4 were the first to detect and characterize in the lens
members of the family of GTP-binding proteins—small
GTPases in the range of 20–30 kDa. At the same time,
the authors identified what they concluded to be a new
class of GTP-binding proteins: three distinct proteins
ranging from 33 to 45 kDa. Because these three GTP-
binding proteins were exclusively associated with the
cortex and nucleus (i.e., fiber cells) and were not found
in heart or brain tissue, the investigators believe they may
be distinct from small GTPases (20–30 kDa) as well as
from heterotrimeric GTPases. Taken together, the detec-
tion of two types of GTP-binding proteins in the lens
pointed to their involvement in such important cellular
regulatory functions as growth, differentiation, and cy-
toskeleton organization. Furthermore, the likelihood that
small GTPases play a significant role in these functions
in the lens supports observations by Rao et al.4 and oth-
ers linking these regulatory proteins to cataract formation
via both genetic mutation and drug toxicity.
Through their role in lens cell differentiation—estab-
lished in 1964 by the first description of microtubules in
lengthening lens fibers—cytoskeletal proteins have been
directly implicated in the formation of cataracts.5 Al-
though cytoskeletal proteins such as actin make up less
than 5% of the proteins found in the lens, they are thought
to serve perform critical functions related to lens trans-
parency. In transparent lens cells, spatial fluctuations in
the refraction index are small compared to the wavelength
of visible light, and the cytoskeletal proteins are uni-
formly distributed. When the proteins form an insoluble
mass large enough to approximate the dimensions of the
wavelength of light, the index of refraction is enlarged,
increasing the scattering of light, and dense opacification
occurs. Among the biochemical changes that have been
reported in human cataracts is the loss of cytoskeletal
proteins, including actin. In a study of cataracts induced
by selenite injection in rats, Matsushima et al.5 found that
the formation of cataracts due to opacification and ag-
gregation of insoluble proteins was associated with a
rapid decrease in 1-crystallin and several cytoskeletal
proteins, including actin. The investigators also found
that, by administering pantethine, a known anti-cataract
agent, loss of cytoskeletal proteins could be inhibited
along with opacification, and cataracts never developed.
In fact, actin concentration in the lens nucleus increased
in the rats treated with pantethine, while noncrystallin
proteins with molecular masses of 42, 55/57, and 235
kDa—labeled with antibodies against actin, tubulin/vi-
mentin, and spectrin, respectively—were degraded dur-
ing the earliest phases of cataract formation in rats in-
jected with selenite. Finding that the loss of noncrystallin
proteins may play an important role in the early phases
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of selenite cataract formation points to the importance of
the vimentin-actin-tubulin component in establishing a
transparent cell structure during lens differentiation in the
cortex. Because crystallins were observed in the selenite
cataract undergoing the process of partial proteolysis and
insolubilization similar to what they undergo from birth
to 4 months of age in the normal lens nucleus, the changes
in protein composition during normal differentiation may
require the same interactions between cytoskeleton and
crystallins that they observed in the selenite cataracts.
Loss of cytoskeletal proteins was associated with an ab-
normal variation in phase-separation temperature by day
3 following selenite injection and with membrane dam-
age and loss of fiber structure by day 2 to 3, indicating
that a properly organized cytoskeleton may be necessary
for normal development and maintenance of transparent
lens structure.5
More recent research has associated actin cytoskeleton
with such eye problems as retinal detachments and
corneal disease as well as cataracts—in some cases, in
further association with drug toxicity. Earlier studies had
established that pharmacologically induced deterioration
of cytoplasmic microfilaments results in submembrane
alterations and then weakening of cellular adhesions in
such cell types as those of the human trabecular mesh-
work.40 In a study in which HTM cells were treated with
the actin-disrupting agent latrunculin-A (LAT-A) known
to increase ocular outflow and reduce intraocular pres-
sure, Cai et al.40 found that the drug induced marked but
reversible rounding of the HTM cells as well as rapid but
reversible loss of actin filaments and disruption of cellu-
lar adhesions. The results lead the authors to the view
that interactions involving HTM cells and the underlying
extracellular matrix may represent a target for pharma-
cological control of intraocular pressure. Because LAT-
A exerts a facility-increasing control effect that is re-
versible in monkeys within 3 h after the drug is stopped,
LAT-A may function by inducing a physiological mod-
ulation of a basic control mechanism instead of causing
irreversible toxicity. Clinical applicability of LAT-A may
be possible by targeting the drug specifically to the cells
of the conventional outflow pathway. To achieve optimal
outflow facility enhancement without increasing the risk
of irreversible changes in the pathway or related tissues,
the authors called for more research on the assembly and
disassembly of actin and actin-associated adhesion pro-
teins of HTM cells treated with LAT-A and other agents.
Cai et al.40 concluded that, because the high concentra-
tions of LAT-A in small volumes typically used in topi-
cal drug protocols and clinical therapy can potentially
harm the cornea, use of lower concentrations in large vol-
umes should be explored. Three years later, members of
this same research group reported results demonstrating
the mitigating effects of LAT-A on alterations to actin
organization and other changes induced by dexametha-
sone.10 Changes induced in HTM cells caused by gluto-
corticosteroids such as dexamethasone are known to in-
clude actin cytoskeletal reorganization, which, when
combined with other effects of the drug, may lead to glau-
coma.41,42 The ability of LAT-A to inhibit the effects of
dexamethasone on the actin cytoskeleton in cultured
HTM cells at a dose below the threshold for increasing
outflow facility in monkeys suggests that LAT-A at low
doses may be useful in treating glaucoma.
Other studies published in the past 3–4 years have
linked the actin cytoskeleton to other forms of corneal
disease, the world’s most common form of bilateral blind-
ness, and to retinal disease.1,9 The presence of Rho-as-
sociated protein kinase in rabbit cornea was linked to de-
layed epithelial cell migration—a cause of numerous
disorders of the corneal epithelium—through the effects
of several agents, including LPA, a Rho activator; ex-
oenzyme C3, a Rho inhibitor; and cytochalasin B, an in-
hibitor of actin filament assembly.1 Two years later, phe-
notypes in the mouse mutants corneal disease-1 (corn1)
and corneal disease-12J (corn12J) were shown to be
caused by mutations within the destrin gene, more com-
monly referred to as ADF.9 Destrin, which is a member
of the ADF/cofilin family of regulatory proteins respon-
sible for enhancing the turnover of actin in vivo, is nor-
mally highly expressed in the corneal epithelium. Based
on their observations that the two corn1 mutations were
deficient in destrin and increased the content of F-actin
in corneal epithelial cells, Ikeda et al.9 concluded that the
proper regulation of actin dynamics is necessary for nor-
mal maintenance of the corneal epithelium and suggested
a new pathway through which aberrant actin cytoskele-
ton leads to epithelial proliferation. Similarly, cellular
and cytoskeletal alterations observed in explant cultures
of porcine neural retina detached from the retinal pig-
mented epithelium resembled degenerative changes seen
following induced retinal detachments.8 The association,
involving such alterations as the frequent, thick bundling
of F-actin seen across the width of the retina, suggests
that the cytoskeleton of individual cell types may play a
key role in retinal damage.
The role of Rho and Rac GTPases, particularly their
induced activation and inhibition in human lens epithe-
lial cells, serves as a further link between the actin cy-
toskeleton and drug toxicity.43 As already discussed, ear-
lier studies have suggested a role for the small GTPases
in lens growth and development and in the maintenance
of lens function, through such molecular mechanisms as
membrane localization in various signal transduction
pathways. For such mechanisms to occur, the small GT-
Pases must undergo a process known as post-translational
isoprenylation involving mevalonic acid and its deriva-
tives, geranylgeranyl and farnesyl isoprenoids. Inhibition
of the production of mevalonate and its isoprenoid de-
rivatives, thus impairing small GTPase function, can be
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caused by 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors used to reduce choles-
terol. Such HMG-CoA reductase inhibitors as lovastatin,
simvastatin, and related compounds have been shown to
cause cataracts in experimental models, and a mutation
in mevalonate kinase has been associated with catarac-
togenesis in humans.44,45 In previous studies, Rao et al.4
found that the inhibition of small GTPase isoprenylation
in lens epithelial cells treated with lovastatin led to sig-
nificant changes in cell shape and reduced epithelial pro-
liferation. Suggesting that such changes potentially acti-
vate cell death pathways as well as alteration to the
cytoskeleton, the authors hypothesized that lovastatin-in-
duced cataractogenesis may stem, at least in part, from
impaired Rho and Rac GTPase function. In a study pub-
lished in 2001, members of the same research group ob-
served dramatic changes in human and porcine lens ep-
ithelial cells—marked by a “profound” loss of such
components as actins stress fibers and focal adhesions—
following treatment with lovastatin.2 The authors also de-
tected a resultant increase in nonisoprenylated Rho and
Rac GTPases. By demonstrating that inhibition of GT-
Pase isoprenylation by lovastatin leads to cellular loss
and disruption of actin cytoskeletal organization, the re-
sults suggest that impairment of Rho and Rac GTPase
function is, in the investigators’ view, “most likely re-
sponsible” for lovastatin-induced changes in lens epithe-
lial cells. In a 2003 study showing that pretreatment with
such GTPase-inhibiting agents as lovastatin negated
growth-factor stimulation of actin stress fiber formation
in human lens epithelial cells, Maddala et al.3 found that
the actin cytoskeleton “constitutes one of the critical
down stream targets of growth factor activity in lens ep-
ithelial cells.” They concluded that the ability of growth
factors to activate actinomyosin cytoskeletal reorganiza-
tion as well as Rho and Rac GTPases may be a critical
factor in the proliferation, migration, elongation, and sur-
vival of lens epithelial cells.
Interestingly, the association of HMG-CoA reductase
inhibitors such as lovastatin and related compounds with
cataractogenesis may be due to a mechanism that has also
been identified as a possible contributing factor to the an-
ticancer activity of another commonly prescribed agent
linked to cataracts, tamoxifen.43 The risk of cataracts has
been shown to increase when cholesterol biosynthesis in
the ocular lens is disrupted, such as by pharmacologic in-
tervention.46 Although statins—which, as a class, are the
most prescribed drugs in the United States—have not
been linked directly to cataractogenesis in humans, inhi-
bition of HMG-CoA reductase has been shown to in-
crease the risk of cataracts in humans, tripling the risk in
patients who received simvastatin concomitantly with
two or more courses of erythromycin.47 A new genera-
tion of hypocholesterolemic drugs known as oxidosqua-
lene cyclase inhibitors offers less secondary increase of
HMG-CoA reductase, among other pharmacologic ad-
vantages; however, these drugs may be more cataracto-
genic than statins. One oxidosqualene cyclase inhibitor,
U18666A (developed by Pharmacia-Upjohn), has been
associated with irreversible lens damage within several
weeks after initiation of treatment, effects that could con-
tribute to the formation of cataracts.43 In a study designed
to test the hypothesis that cataracts caused by U18666A
may be linked to direct perturbation of lens membrane
structure and function, Cenedella et al.43 assessed alter-
ations to membrane order or fluidity by measuring
changes in fluorescent probe anisotropy and through the
use of small-angle x-ray diffraction. Based on observa-
tions made using these methods, the investigators found
that the presence of U18666A in animal lens lipid mod-
els increased membrane structural order and, through the
drug’s intercalation into the cell membranes, resulted in
a broad condensing effect on membrane structure. Ex-
posure to U18666A also induced apoptosis, which may
have been another result of the intercalation that took
place. In considering several hypotheses about the mech-
anism of the drug’s toxicity, the authors cited evidence
suggesting that the resulting cataracts cannot be ex-
plained solely by the ability of U18666A to restrict the
level of cholesterol and that the toxic effects on the lens
cell are due, instead, to an independent factor. A more
likely explanation, in their view, is that direct intercala-
tion of U18666A into the membrane bilayer, by leading
to changes in the membrane structure, contributes to
cataractogenesis. The anticancer effect of tamoxifen—
which, like U18666A, is a liphophilic-amphipathic-
ethoxy tertiary amine—may be partially derived from the
agent’s ability to perturb membrane structure.48 It is per-
haps not surprising, then, that treatment with tamoxifen
is associated with an increased risk of cataracts.49
For the purposes of the study we undertook involving
actin, several factors suggested that tamoxifen was an ap-
propriate choice to demonstrate the effects of drug tox-
icity on the cytoskeleton. A nonsteroidal, oral anti-estro-
gen, tamoxifen has been widely used to treat advanced
breast cancer and as postoperative therapy in patients
with early-stage disease.26 Based largely on the findings
of the National Surgical Adjuvant Breast and Bowel Proj-
ect’s Breast Cancer Prevention Trial (P-1) showing a re-
duced incidence of breast cancer among high-risk women
receiving the drug, tamoxifen was approved by the U.S.
Food and Drug Administration for preventive use, fur-
ther expanding the large population of women using the
agent.64
Although tamoxifen has been shown to be generally
well tolerated for a hormonal agent, its use has been as-
sociated with certain well-documented adverse effects.
The earliest reports of ocular toxicity were made in 1978,
and these were case reports of retinopathy in women be-
ing treated with very high doses for metastatic breast can-
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cer.50 Since these early reports, regular treatment with
low-dose tamoxifen (20–40 mg/day) has been associated
with bilateral optic neuritis,51–53 corneal deposits,54,55
retinal changes,56 glaucoma and macular degeneration,26
crystalline retinopathy,57 optic neuropathy,58 visual acu-
ity abnormalities, macular edema, corneal opacities, and
lens changes, among other forms of ocular toxicity.59 In-
vestigators conducting the Breast Cancer Prevention Trial
found that patients receiving tamoxifen had an increased
risk of cataracts.26 The incidence of toxic reactions to ta-
moxifen has been estimated to be between 0.9% and 12%,
with the incidence of retinopathy in particular estimated
at approximately 5%.60 Colley and Elston58 reported that
this latter form of toxicity has been reversible in the ma-
jority of cases and suggested that prompt cessation of
therapy may lead to visual recovery even in the case of
toxic optic neuropathy. However, in a case report on 
tamoxifen maculopathy,60 it was concluded that halting
tamoxifen therapy usually stops the progression of ocu-
lar disease but does not necessarily result in visual re-
covery. Based on the results of a follow-up study of
women who participated in a trial assessing the effect of
hormone replacement therapy on breast cancer risk 
suggested that 5 or more years of tamoxifen therapy in-
creases risk of cataracts,61 the investigators recommend
determining baseline visual function before initiating
therapy, with regular eye exams afterward. They stopped
short of suggesting cessation of therapy for those patients
who do develop cataracts.
Taken together, the results of these studies suggest
that tamoxifen ocular toxicity, if arrested early enough,
can often be reversible. However, the mechanism for
such effects, particularly with respect to the retina, re-
mains unclear. As suggested above, there is a suggested
association between axonal degeneration and the for-
mation of crystalline retinal deposits in patients re-
ceiving tamoxifen.50 Alternatively, rats treated sub-
chronically with high doses of tamoxifen were found
to have a generalized lipidosis, leading investigators to
hypothesize that the agent itself, by binding with polar
lipids, inhibits lipid catabolism and promotes the
buildup of drug–lipid complexes in lysosomes.62 With
respect to in vitro tamoxifen toxicity in the human reti-
nal pigmented epithelium, the activity of lysosomal en-
zymes in such cells is inhibited by tamoxifen, just as
we have seen with the phagocytosis of rod outer seg-
ments in retinal pigmented epithelial cell cultures.14,63
Changes in membrane lipids may also provide an ex-
planation of the underlying mechanism; although to our
knowledge, there are no published reports of the effect
of tamoxifen toxicity on the actin cytoskeleton. The re-
ports regarding the phagocytosis of rod outer segments
in the retinal pigmented epithelium suggest that toxic
effects on actin would be demonstrable. The implica-
tion that many of these effects may be reversible also
points up the importance of the relative cytotoxicity of
the tamoxifen concentrations being used.
In our study we showed that cytoskeletal changes re-
sulted from concentrations of tamoxifen ranging from, at
the low end, 1–5 M. These concentrations are among
the lowest seen in trials involving tamoxifen and suggest
that changes in actin cytoskeleton may serve as a more
sensitive marker of retinal and lens toxicity than currently
available assays. In several studies published since 2001,
concentrations of tamoxifen have been shown to be toxic
between 7.2  1.1 M and 20.6 M (50% effective con-
centration) for human retinal pigmented epithelial cells
and as low as 3.6  1.1 M (50% effective concentra-
tion) for pig retinal pigmented epithelial cells, depending
on the duration of exposure.14,31,32,48 Comparable results
have also been obtained when researchers measured val-
ues using mol/L or measured 50% inhibitory concen-
tration values.14,48 In a study of the effects of different
concentrations of tamoxifen and two other agents on the
phagocytosis of rod outer segments by the retinal pig-
mented epithelium, Mannerström et al.14 measured the
phagocytized rod outer segments fluorometrically and as-
sessed drug toxicity with the use of the WST-1 test. While
tamoxifen reduced phagocytic activity in human as well
as pig cells via both measures, the inhibition was induced
at levels of tamoxifen below what the WST-1 test indi-
cated was cytotoxic, suggesting that phagocytic activity
was a more sensitive marker phenomenon to the test com-
pounds than was the basic cytotoxicity. The WST-1 test
offers the advantage of yielding water-soluble cleavage
products, reducing the number of steps needed before
measurements can be made. However, because the
homeostatic regulatory functions of the retinal pigmented
epithelium are critical to the retina as a whole, these func-
tions should be measured along with cytotoxicity. The
retinal pigmented epithelium is an interesting in vitro
model for the evaluation of retinal toxicity; however, in
addition to the WST-1 test, more specific tests and mark-
ers based on the homeostatic functions of the retinal pig-
mented epithelium are needed.
The results of our present study suggest that changes
in the actin cytoskeleton may be one such specific
marker. This assertion is made with several caveats. First,
there is the issue of reproducibility. The results of this
study, particularly with respect to the low cytotoxic con-
centrations of tamoxifen, need to be validated by further
testing by other laboratories as well as our research group.
In addition, the usefulness of actin as a biomarker would
be further validated if similar results could be obtained
using drug compounds besides tamoxifen. These two ap-
proaches represent the future line of research in our lab-
oratory.
A second caveat has to do with the limitations of our
study. Although the study consisted of a series of rela-
tively simple, straightforward experiments using known
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in vivo toxicants producing what we found to be clear re-
sults, the lack of consensus within the field on the un-
derlying mechanism(s) by which tamoxifen affects the
lens and retina makes it difficult to definitely conclude
why the drugs are causing changes in the actin cy-
toskeleton at such low concentrations. Is tamoxifen cy-
totoxicity related to decreased enzymatic activity, or is it
due to the alternative explanation of simple reduced
phagocytic activity? The latter may be attributable to such
drug/membrane interactions as protein C kinase activa-
tion induced by tamoxifen and occurring via the phos-
pholipase pathway.48 Further research is needed to iden-
tify the precise role of the actin cytoskeleton in any of
these processes.
Finally, there is the question of the utility of an actin
cytoskeletal biomarker in drug screening for ocular tox-
icity due to its ubiquitous nature in cell biology. Yet, the
opportunity exists to build on this review to develop
screening assays that are more sensitive and specific to-
ward their intended purpose. For ocular toxicity, prese-
lecting compounds based on their ability to alter the actin
cytoskeleton in cells may be an appropriate mechanism
to prioritize development candidates. Such screening of
drugs used for chronic treatment of debilitating or life-
threatening diseases can be controversial, as reported
with respect to hydroxychloroquine and chloroquine ret-
inopathy due to overdosing, where the debate revolved
around the ability of ophthalmologic tests to detect early
retinopathy.27 Although dosing options—including the
decision to continue or discontinue a drug exhibiting oc-
ular toxicity—will belong to the physician treating the
original disease, informed consent of patients experienc-
ing adverse ocular effects can be improved with the use
of more precise ophthalmologic tests and markers.
The development of drug safety screens is untradi-
tional in the sense that most screens are out to qualify
a drug target or screen compounds to a target on the
basis of efficacy. Toxicology, on the other hand, is a
sensitive measure of the exaggeration of pharmacology,
but really lacks specificity. The present study has pro-
vided a potential application for a simple observation,
and others are encouraged to apply their molecular
screens to answer questions in toxicology. The present
extensive discussion is provided so that groups cur-
rently investigating actin biology may broaden the use
of their molecular efforts to try to ascribe a mechanism
to the observations described here. This may be the link
needed to increase the specificity of the ocular toxicity
observation. In this manner, researchers may not only
be able to report that cataracts were observed, but that
they were produced by a perturbation of a specific bio-
chemical pathway. With this knowledge, it is possible
for medicinal chemists to alter a particular test com-
pound to not stimulate this pathway. This is just one
way that a compound could be de-risked, which is a
term commonly used when obtaining a balance between
compound efficacy and safety. Our findings suggest
that the actin cytoskeleton may have a role in such a
clinical advance.
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